SEC Info - Revance Therapeutics, Inc. - ‘10-Q’ for 3/31/16

SEC Info℠

Home

Help

Please Sign In

Revance Therapeutics, Inc. – ‘10-Q’ for 3/31/16 – ‘EX-101.SCH’

On: Tuesday, 5/10/16, at 4:11pm ET · For: 3/31/16 · Accession #: 1479290-16-39 · File #: 1-36297

  As Of               Filer                 Filing    For·On·As Docs:Size

 5/10/16  Revance Therapeutics, Inc.        10-Q        3/31/16   56:3.9M

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    559K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     26K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     26K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
12: R1          Document and Entity Information                     HTML     37K 
13: R2          Condensed Consolidated Balance Sheets               HTML     92K 
14: R3          Condensed Consolidated Balance Sheets               HTML     42K 
                (Parenthetical)                                                  
15: R4          Condensed Consolidated Statement of Operations and  HTML     75K 
                Comprehensive Loss                                               
16: R5          Consolidated Statements of Cash Flows               HTML    110K 
17: R6          The Company and Basis of Presentation               HTML     32K 
18: R7          Summary of Significant Accounting Policies          HTML     30K 
19: R8          Medicis Settlement                                  HTML     28K 
20: R9          Cash Equivalents and Investments                    HTML     90K 
21: R10         Fair Value Measurements                             HTML     87K 
22: R11         Notes Payable and Financing Obligations             HTML     33K 
23: R12         Interest Expense                                    HTML     37K 
24: R13         Commitments and Contingencies                       HTML     39K 
25: R14         Warrants                                            HTML     21K 
26: R15         Stock Option Plan                                   HTML     65K 
27: R16         Net Loss per Share Attributable to Common           HTML     45K 
                Stockholders                                                     
28: R17         Summary of Significant Accounting Policies          HTML     30K 
                (Policies)                                                       
29: R18         Cash Equivalents and Investments (Tables)           HTML     89K 
30: R19         Fair Value Measurements (Tables)                    HTML     82K 
31: R20         Notes Payable and Financing Obligations (Tables)    HTML     24K 
32: R21         Interest Expense (Tables)                           HTML     36K 
33: R22         Commitments and Contingencies (Tables)              HTML     26K 
34: R23         Stock Option Plan (Tables)                          HTML     54K 
35: R24         Net Loss per Share Attributable to Common           HTML     46K 
                Stockholders (Tables)                                            
36: R25         The Company and Basis of Presentation - Additional  HTML     40K 
                Information (Detail)                                             
37: R26         Medicis Settlement - Additional Information         HTML     46K 
                (Detail)                                                         
38: R27         Cash Equivalents and Investments (Details)          HTML     45K 
39: R28         Cash Equivalents and Investments - Remaining        HTML     27K 
                Contractual Maturities Available-for-Sale                        
                Securities (Details)                                             
40: R29         Fair Value Measurements - Schedule of Fair Value    HTML     57K 
                of Financial Instruments (Detail)                                
41: R30         Fair Value Measurements - Summary of Changes in     HTML     25K 
                Fair Value of Financial Instruments (Detail)                     
42: R31         Notes Payable and Financing Obligations - Hercules  HTML     24K 
                Notes Payable (Detail)                                           
43: R32         Notes Payable and Financing Obligations - Essex     HTML     41K 
                Capital Notes (Detail)                                           
44: R33         Notes Payable and Financing Obligations - Summary   HTML     25K 
                of Aggregate Total Future Minimum Lease Payments                 
                under the Financing Obligation (Detail)                          
45: R34         Interest Expense - Summary of Interest Expense by   HTML     32K 
                Cash and Non-Cash Components (Detail)                            
46: R35         Commitments and Contingencies - Additional          HTML     31K 
                Information (Detail)                                             
47: R36         Commitments and Contingencies - Schedule of Future  HTML     34K 
                Minimum Lease Payments under Non-Cancelable                      
                Operating Leases (Detail)                                        
48: R37         Warrants - Additional Information (Detail)          HTML     22K 
49: R38         Stock Option Plan - Additional Information          HTML     42K 
                (Detail)                                                         
50: R39         Stock Option Plan - Fair Value Assumptions          HTML     40K 
                (Details)                                                        
51: R40         Stock Option Plan - Schedule of Stock-based         HTML     27K 
                Compensation Expense (Details)                                   
52: R41         Net Loss per Share Attributable to Common           HTML     40K 
                Stockholders - Schedule of Computation of Basic                  
                and Diluted Net Income (Loss) Per Share                          
                Attributable to Common Stockholders (Detail)                     
53: R42         Net Loss per Share Attributable to Common           HTML     32K 
                Stockholders - Summary of Common Stock Equivalents               
                Excluded from Computation of Diluted Net Income                  
                (Loss) Per Share (Detail)                                        
55: XML         IDEA XML File -- Filing Summary                      XML     96K 
54: EXCEL       IDEA Workbook of Financial Reports                  XLSX     48K 
 6: EX-101.INS  XBRL Instance -- rvnc-20160331                       XML    990K 
 8: EX-101.CAL  XBRL Calculations -- rvnc-20160331_cal               XML    143K 
 9: EX-101.DEF  XBRL Definitions -- rvnc-20160331_def                XML    233K 
10: EX-101.LAB  XBRL Labels -- rvnc-20160331_lab                     XML    838K 
11: EX-101.PRE  XBRL Presentations -- rvnc-20160331_pre              XML    482K 
 7: EX-101.SCH  XBRL Schema -- rvnc-20160331                         XSD     99K 
56: ZIP         XBRL Zipped Folder -- 0001479290-16-000039-xbrl      Zip    111K

‘EX-101.SCH’ — XBRL Schema — rvnc-20160331

This Exhibit is an XBRL XML File.

<?xml version="1.0" encoding="windows-1252"?>

<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.revance.com/20160331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:rvnc="http://www.revance.com/20160331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">

<xsd:import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd"/>

<xsd:import namespace="http://fasb.org/us-roles/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-roles-2015-01-31.xsd"/>

<xsd:import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd"/>

<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>

<xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>

<xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>

<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>

<xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>

<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>

<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>

<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/exch/2015-01-31" schemaLocation="http://xbrl.sec.gov/exch/2015/exch-2015-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>

<xsd:annotation>

<xsd:appinfo>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20160331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20160331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20160331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20160331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>

<link:roleType id="CashEquivalentsAndInvestments" roleURI="http://www.revance.com/role/CashEquivalentsAndInvestments">

<link:definition> 2104100 - Disclosure - Cash Equivalents and Investments </link:definition>

<link:usedOn> link:presentationLink </link:usedOn>